BeStock  
Stocks › Biotechnology › SLN

Silence Therapeutics SLN

US equityMarket cap rank #3610Biotechnology
$9.82 −$0.01 (-0.10%)
Pre-market · Oct 8, 8:20 am ET · After hours $9.82 0.00%
Open$9.77
Prev close$9.83
Day range$9.60 – $10.14
Volume1.32M
Market cap$610.35M
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-7.6x
CheapRich

Around its usual level · 41st percentile, 5-year average -7.8x

Price / book15.9x
CheapRich

Above its usual level · 65th percentile, 5-year average 11.2x

#5033 of 5317 stocks by PB (1 = cheapest)

Price / sales992.4x
CheapRich

Near the top of its 5-year range · 97th percentile, 5-year average 99.2x

#5071 of 5146 stocks by PS (1 = cheapest)

P/E over five years

-21x-14x-7x-1xOct '21Apr '24Oct '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$8.44
Price vs. fair value+16.4%Trading above the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyExtreme
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 15.86 – 11.18 65% (pricier than usual) #5033 of 5317 (1 = cheapest)
PE -7.61 -8.61 -7.75 41% (cheaper than usual) –
PS 992.44 1,004.20 99.16 97% (pricier than usual) #5071 of 5146 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Morningstar view

Star rating★★★
Fair value estimate$8.44
Economic moatNone
UncertaintyExtreme

Discussion

No comments yet — be the first to weigh in on SLN.

Leave a comment

Scroll to Top